Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "cancers"

311 News Found

HCG Manavata launches awareness campaign for prostate cancer
News | September 17, 2025

HCG Manavata launches awareness campaign for prostate cancer

Encouraging early detection and breaking the silence around men’s health


GSK forays into oncology in India with Jemperli and Zejula
News | August 25, 2025

GSK forays into oncology in India with Jemperli and Zejula

The company is bringing precision therapies for gynaecological cancers


Asian Institute of Nephrology & Urology expands hospital in Banjara Hills, Hyderabad
News | August 12, 2025

Asian Institute of Nephrology & Urology expands hospital in Banjara Hills, Hyderabad

AINU is set to accelerate its expansion footprint, enhance operational capabilities


Beta-HPV can directly cause skin cancer in immunocompromised people
News | August 03, 2025

Beta-HPV can directly cause skin cancer in immunocompromised people

cSCC is one of the most common cancers in the U.S. and globally


Imfinzi granted Priority Review and Breakthrough Therapy Designation in US
News | July 31, 2025

Imfinzi granted Priority Review and Breakthrough Therapy Designation in US

For patients with resectable early-stage gastric and gastroesophageal junction cancers


Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl
Clinical Trials | July 19, 2025

Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl

Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use


Ichnos Glenmark Innovation announces global commercialization strategy for ISB 2001
News | July 11, 2025

Ichnos Glenmark Innovation announces global commercialization strategy for ISB 2001

IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China


Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity
Biotech | July 08, 2025

Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity

Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need


Godavari Biorefineries' anti-cancer patent now validated in Spain and UK
Biotech | July 07, 2025

Godavari Biorefineries' anti-cancer patent now validated in Spain and UK

Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states


RedHill Biopharma initiates Expanded Phase 2 Study combining Opaganib and Darolutamide in advanced prostate cancer
Clinical Trials | July 03, 2025

RedHill Biopharma initiates Expanded Phase 2 Study combining Opaganib and Darolutamide in advanced prostate cancer

Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.